tradingkey.logo

Sanofi To Acquire Blueprint Medicines

ReutersJun 2, 2025 5:04 AM

- Sanofi SASY.PA:

  • PRESS RELEASE: SANOFI TO ACQUIRE BLUEPRINT MEDICINES, EXPANDING PORTFOLIO IN RARE IMMUNOLOGICAL DISEASE AND ADDING EARLY-STAGE PIPELINE IN IMMUNOLOGY

  • SANOFI TO FINANCE DEAL WITH CASH AND NEW DEBT

  • SANOFI EXPECTS TO COMPLETE ACQUISITION IN Q3 2025

  • WILL PAY $129.00 PER SHARE IN CASH AT CLOSING, REPRESENTING AN EQUITY VALUE OF APPROXIMATELY $9.1 BILLION FOR BLUEPRINT

  • ACQUISITION IMMEDIATELY ACCRETIVE TO GROSS MARGIN

  • BLUEPRINT SHAREHOLDERS WILL RECEIVE ONE NON-TRADEABLE CONTINGENT VALUE RIGHT (CVR) WHICH WILL ENTITLE HOLDER TO RECEIVE TWO POTENTIAL MILESTONE PAYMENTS OF $2 AND $4 PER CVR FOR ACHIEVEMENT, RESPECTIVELY, OF FUTURE DEVELOPMENT AND REGULATORY MILESTONES FOR BLU-808

  • TOTAL EQUITY VALUE OF BLUEPRINT TRANSACTION, INCLUDING POTENTIAL CVR PAYMENTS, REPRESENTS APPROXIMATELY $9.5 BILLION ON A FULLY DILUTED BASIS

Further company coverage: SASY.PA

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI